Omeros (NASDAQ:OMER) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

Omeros Trading Down 2.9 %

Shares of OMER opened at $6.75 on Tuesday. The firm has a market cap of $391.14 million, a price-to-earnings ratio of -2.92 and a beta of 1.47. Omeros has a 52 week low of $1.38 and a 52 week high of $7.51. The stock has a 50 day moving average of $4.14 and a 200-day moving average of $4.10.

Hedge Funds Weigh In On Omeros

Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its position in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares during the last quarter. MML Investors Services LLC increased its stake in shares of Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the period. SPC Financial Inc. bought a new position in Omeros in the 3rd quarter worth approximately $77,000. SG Americas Securities LLC bought a new position in Omeros in the 3rd quarter worth approximately $80,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in Omeros in the 1st quarter valued at approximately $85,000. 48.79% of the stock is owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.